Merial launches poultry vaccine in China

06-05-2011 | | |

Merial’s VAXXITEK HVT + IBD, a high-technology vector vaccine which protects chickens against infectious bursal disease (IBD) and Marek’s disease has been launched in China.

The launch took place in Hangzhou city on 18 April in front of an invited audience of producers and veterinarians.  Speaking at the event, Professor BI (Chairman Wen Central Research Institute) said: ‘In terms of IBD control, VAXXITEK HVT + IBD will be magical for China’s poultry industry. As we experienced first hand at Wen with our 700 million color broiler production, VAXXITEK HVT + IBD is convenient to use, controls vaccination better and improves feed conversion.” 

VAXXITEK HVT + IBD is registered in 66 countries around the world. First was Brazil where over 5 billion birds have been vaccinated since launch in 2006. Addressing the audience in Hangzhou, Dr Fabricio Delgado of Brazil Foods said: “We have used VAXXITEK HVT + IBD for four years.  It improves performance, especially feed conversion and delivers a great return on investment for our business. As a hatchery vaccine, VAXXITEK HVT + IBD is also beneficial for biosecurity.” 

VAXXITEK HVT + IBD has demonstrated significant advantages over classical vaccines in a number of ways. “Producers only need a single injection, which can be delivered automatically in ovo or in SQ day old birds. Protection continues throughout life and, unlike classic vaccines, VAXXITEK HVT + IBD has little or no immunity gap between the end of maternal antibody protection and the onset of immunity. VAXXITEK HVT + IBD has been proven worldwide under various types of IBD challenges,” said Merial Head of Global Avian Technical Services, Dr Stéphane Lemière.

Source: Merial